Our Primary Research, Products and Analytics help pharma/biotech companies understand the levels and types of payer access that will be required for launch products to achieve their sales forecasts within the first 5 years post-launch.

As some of the first individuals in the industry to develop and refine “bottom-up” payer account level forecasting methodologies, our team offers a history of demonstrated sales forecasting accuracy for U.S. launches. SkyLaunch products combine the power of in-depth data analytics with extensive expertise in managed markets access to create powerful payer access and sales forecasting tools. Pharma/biotech companies have used our tools both to create new sales forecasts and payer access strategies, as well as to validate existing ones.